Skip to content

An Introduction to the Renal Research Institute

The Renal Research Institute: Advancing Research and Improving Kidney Patient Outcomes

Founded in 1997 as a joint venture between Beth Israel Hospital, Manhattan, and Fresenius Medical Care (FME), the Renal Research Institute (RRI) is a world-renowned innovation hub headquartered in New York, New York, and is wholly owned by FME. Its mission is to improve kidney patient outcomes through research.

Currently led by Peter Kotanko, MD, FASN, RRI is uniquely positioned to accelerate the pace of scientific discoveries and their translation into applied medicine. RRI conducts research into advanced fields such as artificial intelligence, metabolomics, and proteomics. Regarding translational and clinical research, RRI’s strength is its end-to-end study capability, including ideation, protocol development, fulfilling regulatory requirements (e.g., protocol submission to institutional review boards), study execution, statistical analysis, publication of results, generation of intellectual property, and clinical implementation support.

Fueling Ideas Through Partnerships

RRI fosters collaboration with individuals and academic institutions around the world, further promoting a cornucopia of ideas that allows innovation to flourish. RRI maintains partnerships with academic institutions in the United States, Europe, Latin America, Asia, and Africa. Some institutions RRI collaborates with include Weill Cornell Medicine, University of North Carolina School of Medicine, University of Maryland, and University of California Santa Barbara.

Beyond academic partnerships, RRI has a robust Fellow Program that provides MDs and PhDs the opportunity to spend one to two years in New York pursuing their research goals. Fellows have specialties in a variety of backgrounds including nephrology, epidemiology, mathematics, biomedical engineering, data science, and artificial intelligence. Fellows have come from over 40 countries, providing a truly global perspective.

Further, RRI is a founding member of the MONitoring Dialysis Outcomes (MONDO) initiative. According to Dr. Kotanko, MONDO is “one of the world’s largest transcontinental dialysis databases — it comprises treatment-level data from over 40 countries on six continents over a period of two decades. Analysis of MONDO data has generated fundamentally novel insights into the biology of dialysis patients.”

As the group continues to grow, RRI consistently seeks new partnerships to help expand and accelerate renal research. Institutions and individuals interested in collaborating with RRI are encouraged to contact the group directly
 

Forward-Thinking Research

Research and innovation are at the core of RRI’s mission. The breadth of current research and the opportunity for future projects are vast. “RRI’s research spans from multiomics to mathematical modeling, epidemiology, early device development and testing, to clinical research studies,” explains Kotanko.

One research project Kotanko is particularly excited about is the development of virtual clinical trials, or VCTs. According to Kotanko, VCTs use “mathematical ‘twins’ of patients [that] are subjected to different treatments. The results of such VCTs inform the treatment algorithms, some of which are used in 150,000 dialysis patients.”

Operational Excellence

RRI also runs its own cutting-edge laboratory, which helps further clinical trials and analytics. The laboratory team is home to experts in clinical laboratory science, biochemistry, molecular biology, biomedical engineering, molecular diagnostics, and multiomics. Having access to both a world-class laboratory that can seamlessly develop and implement novel analytical methods and a large patient population helps RRI innovate to help improve outcomes for kidney patients.

Shaping the Future of Kidney Care

Inspiring an open dialogue and space to explore new ideas helps RRI move research and innovation forward. As Kotanko explains, “Looking at complex problems through multiple lenses broadens our perspective and opens new avenues of inquiry. The simple words ‘I have a thought’ can spark breakthroughs or change the trajectory of a research project.”

Through the translation of rigorous research into potential medical devices, treatment algorithms, medical diagnostics, and clinical care pathways, RRI continuously works to find novel solutions to complex problems — all to help kidney patients thrive.

Publication date: August 2024

Related content

An investigation of whether antihypertensive medications are associated with an increased risk of Intradialytic Hypotension (IDH).

Our patient stories and company features.